[go: up one dir, main page]

NO20060305L - Spraytorkefremgangsmater for dannelse av faste amorte dispersjoner av legemidler og polymerer - Google Patents

Spraytorkefremgangsmater for dannelse av faste amorte dispersjoner av legemidler og polymerer

Info

Publication number
NO20060305L
NO20060305L NO20060305A NO20060305A NO20060305L NO 20060305 L NO20060305 L NO 20060305L NO 20060305 A NO20060305 A NO 20060305A NO 20060305 A NO20060305 A NO 20060305A NO 20060305 L NO20060305 L NO 20060305L
Authority
NO
Norway
Prior art keywords
spray drying
drugs
polymers
solid amorphous
drying methods
Prior art date
Application number
NO20060305A
Other languages
English (en)
Norwegian (no)
Inventor
Roderick Jack Ray
Dwayne Thomas Friesen
Ronald BEYERINCK
Daniel Elmont Dobry
Dana Marie Settell
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34118937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060305(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20060305L publication Critical patent/NO20060305L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
  • Glanulating (AREA)
NO20060305A 2003-08-04 2006-01-20 Spraytorkefremgangsmater for dannelse av faste amorte dispersjoner av legemidler og polymerer NO20060305L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49240703P 2003-08-04 2003-08-04
US56898904P 2004-05-07 2004-05-07
PCT/IB2004/002519 WO2005011636A2 (fr) 2003-08-04 2004-07-27 Procedes de sechage par atomisation pour former des dispersions amorphes solides de medicaments et de polymeres

Publications (1)

Publication Number Publication Date
NO20060305L true NO20060305L (no) 2006-05-03

Family

ID=34118937

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060305A NO20060305L (no) 2003-08-04 2006-01-20 Spraytorkefremgangsmater for dannelse av faste amorte dispersjoner av legemidler og polymerer

Country Status (18)

Country Link
US (1) US10383941B2 (fr)
EP (2) EP2283822A3 (fr)
JP (2) JP2007501219A (fr)
KR (1) KR20060087501A (fr)
AR (1) AR045188A1 (fr)
AT (1) ATE548027T1 (fr)
AU (1) AU2004261061A1 (fr)
BR (1) BRPI0413313A (fr)
CA (1) CA2534129A1 (fr)
CL (1) CL2004001884A1 (fr)
IL (1) IL173130A0 (fr)
MX (1) MXPA06001418A (fr)
NO (1) NO20060305L (fr)
NZ (1) NZ544892A (fr)
PT (1) PT1653928E (fr)
RU (1) RU2318495C2 (fr)
TW (1) TWI290852B (fr)
WO (1) WO2005011636A2 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
JP2009501206A (ja) * 2005-07-14 2009-01-15 ファイザー・プロダクツ・インク 非晶質アジスロマイシン粒子の生成方法
WO2007016435A2 (fr) * 2005-07-28 2007-02-08 Isp Investments Inc. Procede d'amelioration des caracteristiques de poudres sechees par atomisation et de materiaux granules, et produits obtenus par ce procede
PT1926476E (pt) * 2005-08-29 2013-07-10 Sanofi Aventis Us Llc Dispersões sólidas amorfas de 7-cloro-n,n,5-trimetil-4-oxo-3- fenil-3,5-di-hidro-4h-piridazino[4,5-b]indole-1-acetamida
GB0518769D0 (en) * 2005-09-14 2005-10-19 Medpharm Ltd Topical formulations
US7524442B2 (en) * 2006-01-10 2009-04-28 Nanomist Systems, Llc Method and device for manufacturing extremely fine particles and porous materials by controlled low temperature drying
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
AR063704A1 (es) 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
EP2061583B1 (fr) * 2006-09-14 2019-04-10 Yissum Research Development Company, of The Hebrew University of Jerusalem Nanoparticules organiques obtenues à partir de microémulsions par évaporation de solvant
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
WO2008076780A2 (fr) * 2006-12-14 2008-06-26 Isp Investments Inc. Valsartan amorphe et production de celui-ci
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
WO2008092057A2 (fr) * 2007-01-26 2008-07-31 Isp Investments Inc. Procédé de traitement de formulation pour produire des produits séchés pour une pulvérisation
WO2008092046A2 (fr) * 2007-01-26 2008-07-31 Isp Investments Inc. Oxcarbazépine amorphe et sa préparation
PT103661B (pt) * 2007-02-23 2010-09-07 Hovione Farmaciencia S A Processo de preparação de minociclina base cristalina
EP2170830B1 (fr) 2007-07-17 2014-10-15 Plexxikon, Inc. COMPOSÉS DE 2-FLUORO-BENZÈNESULFONAMIDE COMME MODULATEURS DE LA KINASE Raf
WO2009026540A1 (fr) * 2007-08-22 2009-02-26 Colorado School Of Mines Conjugués de nanoparticule de lanthanide et leurs utilisations
WO2009073698A1 (fr) * 2007-12-04 2009-06-11 Bracco Imaging S.P.A. Homogénéisation d'un produit radiopharmaceutique en utilisant une technologie de sonification et/ou de rotor-stator pour produire une suspension, une émulsion, un mélange ou une suspension solide homogène d'ingrédients immiscibles
US20090182053A1 (en) * 2007-12-19 2009-07-16 Tong Sun Fenofibric acid amorphous dispersion; method of making; and method of use thereof
CA2732931A1 (fr) * 2008-08-11 2010-02-18 Ratiopharm Gmbh Ambrisentan amorphe
WO2010096464A1 (fr) 2009-02-18 2010-08-26 Boyes Stephen G Conjugués de nanoparticules d'or/lanthanide et leurs utilisations
PT104350A (pt) * 2009-01-23 2010-07-23 Hovione Farmaci Ncia S A Processo de isolamento de tigeciclina
DE102009013611A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
ES2873502T3 (es) 2009-03-27 2021-11-03 Bend Res Inc Proceso de secado por pulverización
CN101602764B (zh) * 2009-03-27 2011-06-29 浙江车头制药有限公司 一种阿昔洛韦2/3水合物的制备方法
WO2010113241A1 (fr) * 2009-03-31 2010-10-07 株式会社島津製作所 Dispositif de déchargement et de raffinage
KR20170058465A (ko) * 2009-04-03 2017-05-26 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
KR101374854B1 (ko) 2009-05-27 2014-03-19 주식회사 삼양바이오팜 생체이용률이 향상된 난용성 약물 함유 미립구 및 그 제조 방법
RU2403049C1 (ru) * 2009-06-04 2010-11-10 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Федерального агентства по здравоохранению и социальному развитию (ГОУВПО ММА им. И.М. Сеченова Росздрава) Способ получения таблеток эритромицина
US9364485B2 (en) 2009-08-31 2016-06-14 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
AU2010315126B2 (en) 2009-11-06 2015-06-25 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2011061748A1 (fr) * 2009-11-19 2011-05-26 Strides Arcolab Limited Prémélange à base de rifaximine
US20110201076A1 (en) 2010-01-22 2011-08-18 Colorado School Of Mines Harvesting micro algae
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
EP2579855B1 (fr) 2010-06-09 2014-09-03 AbbVie Bahamas Ltd. Dispersions solides contenant des inhibiteurs de kinases
WO2011154014A1 (fr) * 2010-06-11 2011-12-15 Gea Process Engineering A/S Séchage contrôlé de l'humidité
EP2579973A4 (fr) * 2010-06-14 2017-01-18 Xspray Microparticles Ab Appareillage et procédé pour la production de particules
JP5728174B2 (ja) * 2010-06-29 2015-06-03 藤崎電機株式会社 循環式の噴霧乾燥装置
WO2012002547A1 (fr) * 2010-07-02 2012-01-05 富士化学工業株式会社 Dispersion solide de bosentan
WO2012014923A1 (fr) * 2010-07-29 2012-02-02 田辺工業株式会社 Procédé de séchage par atomisation à pression réduite et dispositif de séchage par atomisation à pression réduite
EP2611530B1 (fr) 2010-09-03 2019-01-16 Bend Research, Inc. Appareil de séchage par atomisation et procédés d'utilisation de cet appareil
WO2012031129A2 (fr) 2010-09-03 2012-03-08 Bend Research, Inc. Appareil de séchage par pulvérisation et ses procédés d'utilisation
EP2618924A1 (fr) 2010-09-24 2013-07-31 Bend Research, Inc. Procédé et appareil de séchage par pulvérisation à température élevée
RU2456065C2 (ru) * 2010-10-01 2012-07-20 Государственное образовательное учреждение высшего профессионального образования "Тамбовский государственный технический университет" ГОУ ВПО ТГТУ Способ микродозирования наноструктурных материалов
WO2012109075A1 (fr) 2011-02-07 2012-08-16 Plexxikon Inc. Composés et procédés de modulation de kinase, et leurs indications
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
JP5522577B2 (ja) 2011-08-08 2014-06-18 ヤマトミシン製造株式会社 縫目のほつれ止め装置付二重環縫いミシン
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9962446B2 (en) * 2012-07-17 2018-05-08 Dow Global Technologies Llc Solid dispersion comprising a highly substituted hydroxyalkyl methylcellulose
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
CN105163735B (zh) 2013-02-01 2018-12-11 格力尔罗格克斯股份有限公司 用于治疗神经退行性疾病和其他疾病的组合物和方法
RU2523520C1 (ru) * 2013-04-23 2014-07-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Тамбовский государственный технический университет" ФГБОУ ВПО ТГТУ Способ энергосберегающей сушки гранулированных полимерных материалов
BR112016011605A8 (pt) * 2013-11-22 2023-04-25 Merck Sharp & Dohme Composição de um inibidor de transcriptase reversa não nucleosídeo
BR112016021023A2 (pt) * 2014-03-11 2021-09-14 Promius Pharma, LLC Composições de corticosteroides tópicos
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US9593078B2 (en) * 2014-05-09 2017-03-14 Abbvie Inc. Crystal forms
ES3009527T3 (en) 2014-07-25 2025-03-27 Laurent Pharmaceuticals Solid oral formulation of fenretinide
JP6650933B2 (ja) 2014-10-31 2020-02-19 ベンド リサーチ， インコーポレイテッド マトリックス中に分散された活性薬剤ドメインを形成するためのプロセス
CA3018812A1 (fr) * 2016-04-29 2017-11-02 Rousselot B.V. Excipient a base de proteines destine a des principes actifs pharmaceutiques
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US20190224584A1 (en) * 2016-10-13 2019-07-25 Capsugel Belgium Nv Process for making spray dried compositions and spray drying apparatus
US20180110760A1 (en) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions and methods for the treatmentof neurodegenerative and other diseases
JP6937016B2 (ja) * 2017-09-06 2021-09-22 東京理化器械株式会社 噴霧乾燥装置
CN107381691A (zh) * 2017-09-12 2017-11-24 哈尔滨锅炉厂环保工程技术有限公司 一种用于湿法烟气脱硫废水蒸发的蒸发炉
CN110582270A (zh) * 2017-11-30 2019-12-17 G2G生物公司 含有多奈哌齐的缓释注射制剂及其制备方法
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ，エルエルシー 消化管間質腫瘍の治療のための併用療法
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
PT110585B (pt) * 2018-02-22 2021-04-22 Hovione Farmaciencia Sa Processo de produção contínua de partículas compreendendo secagem por atomização com preparação contínua da solução de atomização
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
CN112368060B (zh) * 2018-06-29 2023-01-10 基伊埃工程技术股份有限公司 喷雾干燥设备和使气体流在喷雾干燥设备的气体分散器中调准的方法
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
EP3938094A1 (fr) 2019-03-15 2022-01-19 Novo Nordisk A/S Procédé de séchage à pulvérisation d'un peptide glp-1
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
SMT202400484T1 (it) 2019-12-30 2025-01-14 Deciphera Pharmaceuticals Llc Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea
AU2021353684A1 (en) 2020-09-29 2023-06-08 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
EP4259063A4 (fr) * 2020-12-11 2024-12-18 Merck Sharp & Dohme LLC Système de contenant compact pour isoler, traiter et conditionner des produits pharmaceutiques
US20240315996A1 (en) 2021-02-02 2024-09-26 DuPont Nutrition USA, Inc. An aqueous gel composition comprising an ethylcellulose
KR102631642B1 (ko) * 2021-04-19 2024-02-01 주식회사 그랩실 스프레이 건조 시스템 및 스프레이 건조 방법
WO2023158616A1 (fr) * 2022-02-18 2023-08-24 Viking Therapeutics, Inc. FORMES POSOLOGIQUES ORALES DE L'AGONISTE DE TRβ, VK2809, POUR LE TRAITEMENT DE TROUBLES HÉPATIQUES, ET PROCÉDÉS DE PRÉPARATION DE CELLES-CI
KR20250004684A (ko) 2022-03-25 2025-01-08 선전 파마신 컴퍼니 리미티드 Protac 화합물의 약학적 조성물 및 이의 용도
US20240009128A1 (en) * 2022-07-07 2024-01-11 Serán BioScience, LLC Methods and systems for use of low-volatility solvents for spray drying
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024119151A1 (fr) * 2022-12-02 2024-06-06 Serán BioScience, LLC Procédés et systèmes de séchage par pulvérisation de produits sensibles à la température

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL46210C (fr) * 1936-06-19
DE818197C (de) 1950-02-14 1951-10-22 Otto H Dr-Ing E H Hartmann Zweidruckkesselanlage fuer Hochdrucklokomotiven
GB1131242A (en) 1965-02-18 1968-10-23 Gen Foods Ltd Improvements in or relating to spray-drying apparatus
GB1329791A (en) 1971-01-19 1973-09-12 Niro Atomizer As Spray drying devices for the production of powder eg milk powder
IT1025765B (it) 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
US4056599A (en) 1975-10-20 1977-11-01 Bechtel International Corporation Process for the recovery of magnesium chloride hydrate and potassium chloride from carnallite and bischofite
US4187617A (en) 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4702799A (en) 1985-09-03 1987-10-27 Nestec S.A. Dryer and drying method
IT1230095B (it) 1989-04-27 1991-10-05 Parenta Srl Procedimento per la preparazione di forme sterili di polveri iniettabili di antibiotici.
US5000947A (en) 1989-05-30 1991-03-19 Moleculon, Inc. Shaped articles containing liquefiable powders for delivery of cosmetic and other personal care agents
PT96229B (pt) 1989-12-22 1998-06-30 Syntex Pharma Int Processo para a preparacao de composicoes farmaceuticas em po, secas por pulverizacao, directamente compressiveis em comprimidos, contendo naproxeno ou naproxeno sodico
DE69016788T2 (de) 1990-11-29 1995-06-22 Faulding F H & Co Ltd Verfahren zur Herstellung von Flüssigkeiten enthaltenden Pulvern.
KR0159947B1 (ko) * 1991-03-12 1998-11-16 마사아키 오카와라 분수형 가압 2류체 노즐 장치와 그것을 편입하여 이루어지는 스프레이 드라이어 장치, 및 가압 2류체에 있어서의 액적 경 제어법
DE4244466C2 (de) 1992-12-24 1995-02-23 Pharmatech Gmbh Verfahren zur Herstellung von Pseudolatices und Mikro- oder Nanopartikeln und deren Verwendung zur Herstellung von pharmazeutischen Präparaten
NZ283160A (en) 1994-05-06 1998-07-28 Pfizer Azithromycin in a controlled release dosage form for treating microbiol infections
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
DE19542442A1 (de) 1995-11-14 1997-05-15 Wacker Chemie Gmbh Verfahren zur Herstellung von in Wasser redispergierbaren, Organosiliciumverbindungen enthaltenden Pulverzusammensetzungen
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
US20030064108A1 (en) 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
AUPN969796A0 (en) 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
DE19627419A1 (de) 1996-07-08 1998-01-15 Bayer Ag Cycloalkano-pyridine
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
DE19704243A1 (de) 1997-02-05 1998-08-06 Bayer Ag Neue 2-Amino-substituierte Pyridine
DE19704244A1 (de) 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
EP0901786B1 (fr) 1997-08-11 2007-06-13 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
AU9297798A (en) 1997-09-16 1999-04-05 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19832159A1 (de) 1997-09-18 1999-03-25 Bayer Ag Substituierte Tetrahydro-naphthaline
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741400A1 (de) 1997-09-19 1999-03-25 Bayer Ag Benzyl-biphenyle
DE19741399A1 (de) 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
AU3285499A (en) 1998-02-13 1999-08-30 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
RU2144040C1 (ru) * 1998-04-07 2000-01-10 Всероссийский научно-исследовательский и технологический институт биологической промышленности Способ получения натриевой соли сукцината хитозана
US6609102B2 (en) 1998-07-20 2003-08-19 Usa Technologies, Inc. Universal interactive advertizing and payment system for public access electronic commerce and business related products and services
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
EP1115695B1 (fr) 1998-09-25 2005-06-01 Monsanto Company Amino-(n+1)-alcanols 1-substitues halogenes r-chiraux, utiles comme inhibiteurs de l'activite de la proteine de transfert de l'ester de cholesteryle
JP2002525350A (ja) 1998-09-25 2002-08-13 モンサント カンパニー コレステロールエステル輸送タンパク質活性阻害に有効な置換されたｎ−脂肪族−ｎ−芳香族第三級ヘテロアルキルアミン
EP1027887B1 (fr) 1999-02-10 2008-08-13 Pfizer Products Inc. Dispositif pour la libération du principe actif contrôlée par la matrice
EP1027888B1 (fr) 1999-02-10 2009-06-10 Pfizer Products Inc. Dispositif osmotique pour délivrer des dispersions solides amorphes des médicaments
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
AU4133899A (en) 1999-06-08 2000-12-28 Niro A/S A process and a plant for spray drying
WO2001047492A1 (fr) 1999-12-23 2001-07-05 F H Faulding & Co Limited Compositions pharmaceutiques ameliorees pour medicaments peu solubles
PE20011184A1 (es) 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1186347A1 (fr) 2000-09-05 2002-03-13 F. Hoffmann-La Roche Ag Procédé et dispositif de pulvérisation de liquides
US6848197B2 (en) * 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
EP1401399A2 (fr) * 2001-06-22 2004-03-31 Pfizer Products Inc. Compositions pharmaceutiques contenant des ensembles polymere et medicament
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
PL371593A1 (en) * 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
ATE395044T1 (de) * 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
CA2473991C (fr) * 2002-02-01 2009-09-15 Pfizer Products Inc. Forme posologique a liberation controlee d'une proteine inhibant le transfert du cholesteryl ester
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.

Also Published As

Publication number Publication date
ATE548027T1 (de) 2012-03-15
US10383941B2 (en) 2019-08-20
MXPA06001418A (es) 2006-05-15
JP2011016821A (ja) 2011-01-27
EP2283822A3 (fr) 2012-06-13
AR045188A1 (es) 2005-10-19
US20050031692A1 (en) 2005-02-10
CL2004001884A1 (es) 2005-06-03
CA2534129A1 (fr) 2005-02-10
NZ544892A (en) 2008-09-26
RU2318495C2 (ru) 2008-03-10
KR20060087501A (ko) 2006-08-02
EP1653928B1 (fr) 2012-03-07
TWI290852B (en) 2007-12-11
WO2005011636A2 (fr) 2005-02-10
JP2007501219A (ja) 2007-01-25
WO2005011636A3 (fr) 2005-03-31
PT1653928E (pt) 2012-04-13
RU2006103256A (ru) 2006-06-27
IL173130A0 (en) 2006-06-11
AU2004261061A1 (en) 2005-02-10
TW200524675A (en) 2005-08-01
EP1653928A2 (fr) 2006-05-10
BRPI0413313A (pt) 2006-10-10
EP2283822A2 (fr) 2011-02-16

Similar Documents

Publication Publication Date Title
NO20060305L (no) Spraytorkefremgangsmater for dannelse av faste amorte dispersjoner av legemidler og polymerer
BR0210518A (pt) Composições farmacêuticas de dispersões de drogas e polìmeros neutros
Fornasari Pain mechanisms in patients with chronic pain
TNSN03137A1 (fr) Compositions pharmaceutiques comprenant des medicaments de faible solubilite et/ou sensibles aux acides et des polymeres acides neutralises.
EP1988910A4 (fr) Conjugués de polymères contenant de l'acryloyloxyéthylphosphorylcholine et leur préparation
SG170087A1 (en) Pharmaceutical compositions
CY1115891T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση των διαταραχων του εσω ωτος
WO2006138463A3 (fr) Compositions polymeres et conjugues de medicaments anti-inflammatoires non steroides
CY1115005T1 (el) Φαρμακευτικο σκευασμα ανθεκτικο στην καταχρηση
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
MXPA05003591A (es) Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
ATE442841T1 (de) Pegylierte nanoteilchen
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
NO20074109L (no) Intravenose formuleringer av PDE-5 inhibitorer
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
WO2008037557A3 (fr) Médicaments anti-inflammatoires non stéroïdiens solubilisés
WO2008006795A3 (fr) Composés d'indole
WO2006099514A3 (fr) Composition d'administration de medicaments contenant un polymere et un agent modificateur
WO2012024605A3 (fr) Dispositifs et procédés d'administration intravaginale de médicaments et d'autres substances
NO20071806L (no) Tabletter med steds- og tidsregulert gastrointestinal frigivelse av aktiv bestanddel.
WO2006063294A3 (fr) Nouveaux inhibiteurs de l'histone deacetylase permettant de traiter une maladie
TW200700062A (en) Pharmaceutical compositions
WO2008008387A3 (fr) Composition de polyanhydre utilisé pour administrer des médicaments et procédé correspondant
ATE375203T1 (de) Faserreiche fraktion von trigonella-foenum- graecum-samen und verwendung davon als pharmazeutischer exzipient
EA200500418A1 (ru) Лекарственное средство

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application